vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) shares passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $19.30 and traded as high as $19.45. vTv Therapeutics shares last traded at $17.76, with a volume of 4,707 shares.
Analyst Ratings Changes
VTVT has been the subject of a number of recent research reports. Wall Street Zen initiated coverage on vTv Therapeutics in a research note on Wednesday, April 16th. They set a "sell" rating for the company. HC Wainwright began coverage on vTv Therapeutics in a report on Wednesday, April 9th. They issued a "buy" rating and a $36.00 target price on the stock.
Read Our Latest Research Report on vTv Therapeutics
vTv Therapeutics Price Performance
The business has a 50-day simple moving average of $19.29 and a 200 day simple moving average of $17.18. The firm has a market cap of $51.20 million, a PE ratio of -3.54 and a beta of 0.77.
vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The biotechnology company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.04).
Institutional Trading of vTv Therapeutics
Several large investors have recently added to or reduced their stakes in VTVT. Geode Capital Management LLC boosted its stake in shares of vTv Therapeutics by 12.9% in the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company's stock worth $158,000 after buying an additional 1,327 shares during the last quarter. Connective Capital Management LLC purchased a new position in vTv Therapeutics during the first quarter worth approximately $162,000. Finally, JPMorgan Chase & Co. purchased a new position in vTv Therapeutics during the fourth quarter worth approximately $25,000. Hedge funds and other institutional investors own 17.51% of the company's stock.
vTv Therapeutics Company Profile
(
Get Free Report)
vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
See Also
Before you consider vTv Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and vTv Therapeutics wasn't on the list.
While vTv Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
